ArticleProceedings of the National Academy of Sciences of the United States of America2023
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The Crossroads of Neuroinflammation and Biomarkers in Multiple Sclerosis: A Systematic Review.Cells · 2026Pooled it
- Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review.Current pharmaceutical design · 2024Pooled it
- Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.JAMA neurology · 2026Trial
- Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.Scientific reports · 2024Trial
- IgA Deficiency Exacerbates an Animal Model of Multiple Sclerosis Induced with Theiler's Virus.Cells · 2026Article
- Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review.Neurology and therapy · 2026Review
- Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.Neurology and therapy · 2026Article
- Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort.Frontiers in immunology · 2026Article
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy.Annals of neurology · 2025Article
- Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis.Annals of clinical and translational neurology · 2025Article
- Article
- B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.iScience · 2025Article
- CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion.International journal of molecular sciences · 2025Review
- Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis.The Journal of clinical investigation · 2025Article
- The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.CNS drugs · 2025Review
- Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics.iScience · 2025Article
- Reconstitution of CXCR3Annals of clinical and translational neurology · 2025Observational
- The effect of anti-CD20 on inflammation and histopathological alternations in rat photothrombotic ischemic stroke model.Immunologic research · 2025Article
- Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.Cells · 2025Article
Corrections and comments
- Commented on by
Authors and funding
33 authors at 19 institutions in 5 countries.
Koji ShinodaDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-3818-9008
Rui LiDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-7210-8358
Ayman RezkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Ina MexhitajDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Kristina R PattersonDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Mihir KakaraDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-8951-8604
Leah ZuroffDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Jeffrey L BennettDepartments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Aurora, CO 80045.
H-Christian von BüdingenF. Hoffmann-La Roche, 4070 Basel, Switzerland.ORCID 0000-0003-0159-6662
Robert CarruthersDepartment of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada.
Keith R EdwardsMultiple Sclerosis Center of Northeastern New York, Comprehensive MS Care Center Affiliated with the National MS Society, Latham, NY 12110.
Robert FallisDepartment of Neurology, Ohio State University Medical Center, Columbus, OH 43210.
Paul S GiacominiDepartment of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.ORCID 0000-0002-1346-3042
Benjamin M GreenbergDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-2091-8201
David A HaflerDepartments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06510.ORCID 0000-0003-4664-535X
Carolina IoneteDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA 01655.
Ulrike W KaunznerJudith Jaffe Multiple Sclerosis Center, Weill Cornell Medicine, New York, NY 10021.
Christopher B LockDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA 94304.ORCID 0000-0002-4087-5894
Erin E LongbrakeDepartment of Neurology, Yale University, New Haven, CT 06510.
Gabriel PardoOklahoma Medical Research Foundation, Multiple Sclerosis Center of Excellence, Oklahoma City, OK 73104.ORCID 0000-0002-2207-3708
Fredrik PiehlDepartment of Clinical Neuroscience, Karolinska Institute, SE-171 76 Stockholm, Sweden.ORCID 0000-0001-8329-5219
Martin S WeberInstitute of Neuropathology, University Medical Center, 37075 Göttingen, Germany.ORCID 0000-0001-8409-0389
Tjalf ZiemssenDepartment of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technical University of Dresden, 01307 Dresden, Germany.ORCID 0000-0001-8799-8202
Dina JacobsDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Jeffrey M GelfandWeill Institute for Neurosciences, University of California, San Francisco, CA 94158.
Anne H CrossDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO 63110.ORCID 0000-0003-0829-7569
Briana CameronGenentech, Inc., South San Francisco, CA 94080.ORCID 0000-0001-5940-8252
Bruno MuschGenentech, Inc., South San Francisco, CA 94080.
Ryan C WingerGenentech, Inc., South San Francisco, CA 94080.ORCID 0000-0001-9160-6646
Xiaoming JiaGenentech, Inc., South San Francisco, CA 94080.
Christopher T HarpGenentech, Inc., South San Francisco, CA 94080.
Ann HermanGenentech, Inc., South San Francisco, CA 94080.
Amit Bar-OrDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
University of Pennsylvania · USYale University · USChildren's Hospital of Philadelphia · USCornell University · USFraunhofer Institute for Translational Medicine and Pharmacology · DEKarolinska University Hospital · SEMontreal Neurological Institute and Hospital · CANational Multiple Sclerosis Society · USOklahoma Medical Research Foundation · USRoche (Switzerland) · CHStanford University · USThe Ohio State University Wexner Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity Hospital Carl Gustav Carus · DEUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Colorado Denver · USUniversity of Massachusetts Chan Medical School · USWashington University in St. Louis · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MRole of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7MSystems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI RUTH HALABAN · 2006 to 2026
$43.9MTransgenic / Knock-out mouse coreP01AI073748 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BEHAR, SAMUEL M · 2008 to 2019
$17.1M(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitorsR01CA227473 · NCI · YALE UNIVERSITY · PI HEROLD, KEVAN C, KLUGER, HARRIET M. · 2018 to 2022
$3.2MYale Clinical Neuroscientist Training ProgramR25NS079193 · NINDS · YALE UNIVERSITY · PI HAFLER, DAVID A. · 2012 to 2023
$943kUniversity of Pennsylvania Clinical Autoimmunity Center of ExcellenceUM1AI144288 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BAR-OR, AMIT, PAYNE, AIMEE S · 2019 to 2023
$551kNCI NIH HHS P50 CA121974NCI NIH HHS R01 CA227473NIAID NIH HHS P01 AI039671NIAID NIH HHS P01 AI073748NIAID NIH HHS U19 AI089992NINDS NIH HHS R25 NS079193
Abstract
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of CD20-expressing cells with repeat infusions. We assessed cellular immune profiles and their association with transient disease activity following anti-CD20 initiation as a window into relapsing disease biology. Peripheral blood mononuclear cells from independent discovery and validation cohorts of MS patients initiating ocrelizumab were assessed for phenotypic and functional profiles using multiparametric flow cytometry. Pretreatment CD20-expressing T cells, especially CD20
Indexed as
CD8-Positive T-LymphocytesMultiple SclerosisAntigens, CD20Flow CytometryHumansLeukocytes, MononuclearRecurrenceAntigens, CD20anti-CD20 therapyCD20dimCD8+ T cellsCD20dim T cellsCD20-expressing T cellsocrelizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.